Wire Stories
-
20.7KNaturalShrimp Collaborates with Australian Companies in a Prawn Farm Wastewater Trial
DALLAS–(BUSINESS WIRE)–NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS (Recirculating Aquaculture...
-
21.0KNaturalShrimp Collaborates with Australian Companies in a Prawn Farm Wastewater Trial
DALLAS–(BUSINESS WIRE)–NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS (Recirculating Aquaculture...
-
22.5KNaturalShrimp Collaborates with Australian Companies in a Prawn Farm Wastewater Trial
DALLAS–(BUSINESS WIRE)–NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS (Recirculating Aquaculture...
-
22.7KTAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)
Patients underwent BNCT using TAE Life Sciences� Neutron Beam System as part of Neuboron Medical Group�s NeuPex System at Xiamen Humanity Hospital...
-
23.9KTAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)
Patients underwent BNCT using TAE Life Sciences� Neutron Beam System as part of Neuboron Medical Group�s NeuPex System at Xiamen Humanity Hospital...
-
24.5KTAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)
Patients underwent BNCT using TAE Life Sciences� Neutron Beam System as part of Neuboron Medical Group�s NeuPex System at Xiamen Humanity Hospital...
-
23.2KAnteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts
Company Funded Through Results of U.S. Early Feasibility Study of DurAVR� BRISBANE, Australia and EAGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Ltd (ASX: AVR), a...
-
21.0KAnteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts
Company Funded Through Results of U.S. Early Feasibility Study of DurAVR� BRISBANE, Australia and EAGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Ltd (ASX: AVR), a...
-
22.8KAnteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts
Company Funded Through Results of U.S. Early Feasibility Study of DurAVR� BRISBANE, Australia and EAGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Ltd (ASX: AVR), a...
-
22.0KVBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial data suggest VBI-2601 (BRII-179) and BRII-835 combination...
To Top